10533833 - GAU: 1625

10/533833

JCO6 Rec'tl PCT/PTO 03 MAY 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449/PTO Application Number Based on PCT/JP03/14101 Filing Date Intl. Filing 05 NOV 2003 INFORMATION DISCLOSURE First Named Inventor Masahiro KAJINO STATEMENT BY APPLICANT Art Unit tba (Use as many sheets as necessary) **Examiner Name** tba 3116 US0P Attorney Docket Number Sheet 1

			U. S. PATENT	DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (# known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
-	0.4	US- 4 400 000	44/04/4070	10.00	· · ·gar-oo / ·ppod/
	A1	^{US-} 4,126,689	11/21/1978	Stefan Sanczuk, et al.	
	A2	^{US-} 4,791,120	12/13/1988	Bor-Sheng Lin, et al	
		US-			
		US-			
		US-			
		US-			
		US-		· · · · · · · · · · · · · · · · · · ·	
		US-			· .
		US-			
		US-		1915	
		US-			
		US-			
		US-			

		FORE	IGN PATENT DOCL	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T ⁶
	A3	WO 01/44297 A1	06/21/2001	Synaptic Pharmaceutical		
	A4	EP 1255109 A1	11/06/2002	Takeda Chemical Industries		
	A5	WO 00/02919	01/20/2000	Merck & Co., Inc.		П
	A6	EP 1237001 A1	09/04/2002	Takeda Chemical Industries		Т
	A7	JP 01-213279 - Abstract	08/28/1989	BOC Group, Inc.		

Examiner Signature	/John Mabry/ (05/13/2008)	Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10533833 - GAU: 1625

2

10/533833

JC06 Rec'd PCT/PTO 03 MAY 2005

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

	Under the Paperwork Red	uction A	Act of 1995, no persons ar		of information unless it contains a valid OMB control n		
4	Substitute for form 1449/PTO			Complete if Known			
l				Application Number	Based on PCT/JP03/14101	-	
I	INFORMATION	DIS	SCLOSURE	Filing Date	Intl. Filing 05 NOV 2003		
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Masahiro KAJINO		
(Use as many sheets as necessary)				Art Unit	tba		
(coo do many encore as necessary)				Examiner Name	tba		
١	Sheet 2	of	2	Attorney Docket Number	3116 US0P		

Cite		
No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
A8	L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32.	
A9	N. SAKURA, et al., "StructureActivity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, Vol. 48, No. 8.	
A10	M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acting Opiod Agonist, Remifentanil", Synlett, (1999), pp. 1923-1224, No. 12.	
A11	N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3.	
A12	L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7.	
A13	D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155.	
A14	S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41.	
A15	C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52.	
A16	K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1997), pp. 426-434, Vol. 46.	
	A8 A9 A10 A11 A12 A13 A14 A15	number(s), publisher, city and/or country where published. L.V. KUDZMA, et al., "4-Phenyl- and 4-Heteroaryl-4-anilidopiperidines. A Novel Class of Analgesic and Anesthetic Agents", J. Med. Chem., (1989, pp. 2534-2542, Vol. 32. N. SAKURA, et al., "Structure—Activity Relationships of Neuromedin U. IV. Absolute Requirement of the Arginine Residue at Position 7 of Dog Neuromedin U-8 for Contractile Activity", Chem. Pharm. Bull., (2000), pp. 1166-1170, Vol. 48, No. 8. M.J. COLEMAN, et al., "A Convenient Method for the N-Acylation and Esterification of Hindered Amino Acids: Synthesis of Ultra Short Acting Opiod Agonist, Remifentanil", Synlett, (1999), pp. 1923-1224, No. 12. N. MINAMINO, et al., "Neuromedin U-8 and U-25: Novel Uterus Stimulating and Hypertensive Peptides Identified in Porcine Spinal Cord", Biochemical and Biophysical Research Communications, (1985), pp. 1078-1085, Vol. 130, No. 3. L.K. MALENOWICZ, et al., "Effects of Neuromedin U-8 on the Rat Pituitary-Adrenocortical Axis", in vivo, (1993), pp. 419-422, Vol. 7. D.R. Brown, et al., "Neuromedin U Octapeptide Alters Ion Transport in Porcine Jejunum", European Journal of Pharmacology, (1988), pp. 159-162, Vol. 155. S. SUMI, et al., "Effect of Synthetic Neuromedin U-8 and U-25, Novel Peptides Identified in Porine Spinal Cord, on Splanchnic Circulation in Dogs", Life Sciences, (1987), pp. 1585-1590, Vol. 41. C.P. TAN, et al., "Cloning and Characterization of a Human and Murine T-Cell Orphan G-Protein-Coupled Receptor Similar to the Growth Hormone Secretagogue and Neurotensin Receptors", Genomics, (1998), pp. 223-229, Vol. 52. K. K. McKEE, et al., "Cloning and Characterization of Two Human G Protein-Coupled Receptor Genes (GPR38) Related to the Growth Hormone Secretagogue and Neurotensin Receptors",

Examiner	/John Mabry/ (05/13/2008)	Date	
Signature	700/11/10/2000)	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.